Treatment of COVID19 with antimalarial medicines: clinical pharmacology analysis

The COVID-19 epidemic caused by the human coronovirus has led to completely new challenges for clinical pharmacology, and the healthcare system as a whole. By the time the infection started, there was no effective and safe therapy. In this regard, at the request of the society and medical workers, clinical trials and routine use in clinical practice were started simultaneously. This publication provides a clinicalpharmacological analysis of well-known antimalarial medicines, which became one of the first drugs for the treatment of COVID-19 almost all over the world. Pharmacodynamic and pharmacokinetic parameters are presented. Antiviral activity, including on coronavirus, were shown. The main clinical trials for June 2020 were indicated and analyzed. Recommendations and prospects for further research were given